Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Fulminant myocarditis and atrial fibrillation in child with acute COVID-19

Utkarsh Kohli, M.D. a,b,⁎, Elizabeth Meinert, M.D. b, Grace Chong, M.D. b, Melissa Tesher, M.D. c, Priti Jani, M.D., M.P.H. b

a Section of Pediatric Cardiology, Department of Pediatrics, Comer Children’s Hospital and the Pritzker School of Medicine of the University of Chicago, Chicago, IL, United States of America
b Division of Pediatric Critical Care Medicine, Department of Pediatrics, Comer Children’s Hospital and the Pritzker School of Medicine of the University of Chicago, Chicago, IL, United States of America
c Division of Rheumatology, Department of Pediatrics, Comer Children’s Hospital and the Pritzker School of Medicine of the University of Chicago, Chicago, IL, United States of America

⁎ Corresponding author at: Assistant Professor of Pediatrics, Department of Pediatrics, Section of Pediatric Cardiology, University of Chicago Medicine, 5841 S Maryland Ave., Chicago, IL 60637, United States of America.

E-mail addresses: ukohli@peds.bsd.uchicago.edu, utkarshkohli@gmail.com (U. Kohli).

ABSTRACT

COVID-19 has manifested with ventricular dysfunction and cardiac arrhythmias, most commonly atrial fibrillation (AFib), in adults. However, very few pediatric patients with acute COVID-19 have had cardiac involvement. AFib, an exceedingly rare arrhythmia in otherwise healthy children, has not been reported in children with COVID-19. We report a 15 year-old girl with acute COVID-19, fulminant myocarditis and AFib.

Case report

A 15 year-old, previously healthy African-American girl presented with headache, vomiting, and fatigue to an outside emergency room where she was noted to be febrile (101.8 °F), tachycardic (150 bpm) and hypotensive (70/40 mmHg). She was noted to have a history of asthma, hay fever, and seasonal allergies. She denied any history of drug or alcohol abuse and the family history was negative for channelopathy, cardiomyopathy or family history of cardiomyopathy. Her serum electrolytes were within the normal range. She was admitted to our pediatric intensive care unit where an echocardiogram revealed severe left ventricular dysfunction (SF ~ 20%) without any atrial or ventricular dilation (Video 1). No patent foramen ovale was noted. Given the ongoing hypotension and poor ventricular function, therapy was initiated with milrinone (0.7 μg/kg/min) and epinephrine (0.03 μg/kg/min). Serum pro-NT BNP, inflammatory markers and high sensitivity troponin concentration were all markedly elevated (Supplement 1). She was initially treated with intravenous immune globulin (1 g/kg), intravenous methylprednisolone 60 mg every 12 h and subcutaneous low molecular weight heparin (Supplement 1). She was initially treated with intravenous immune globulin (1 g/kg), intravenous methylprednisolone 60 mg every 12 h and subcutaneous low molecular weight heparin (Supplement 1). Epinephrine infusion was discontinued within 12 h. Milrinone (0.7 μg/kg/min) was continued until her ventricular function normalized (day 4). Hypotension recurred 24 h post-admission, and immunomodulatory therapy was therefore intensified via addition of the IL-1 receptor antagonist, anakinra (100 mg subcutaneous every 12 h). She did not require any respiratory support though her chest radiograph showed minimal vascular engorgement. Atrial fibrillation with rapid ventricular conduction (ventricular rate 140 s to 190 s) developed 27 h after admission and she was successfully cardioverted (50 J, synchronized) (Fig. 1). Post-cardioversion, an amiodarone infusion was initiated and 12 h later, transitioned to an oral regimen. Our patient denied a history of drug or alcohol abuse and the family history was negative for channelopathy, cardiomyopathy or early onset AFib. Her serum electrolytes were within the normal range at the time of onset of AFib (Potassium = 3.7 mmol/L, Calcium 9.1 mg/dL and Magnesium 2.2 mg/dL) and her oxygen saturation measured normal during the duration of her hospital stay. Her electrocardiogram in sinus rhythm was normal without any evidence of pre-excitation.

A cytokine panel (ARUP Laboratories, Salt Lake City, UT, USA) obtained on our patient prior to initiation of immunomodulatory therapy revealed elevated plasma concentrations of soluble interleukin (IL) 2 Receptor (soluble) (2670 pg/ml; range: 175.3 to 858.2 pg/ml) and IL-10 (5.4 pg/ml; normal ≤2.8 pg/ml). Plasma IL-2, IL-12, TNF-α, INF-γ, IL-4, IL-5, IL-13, IL-17, IL-1β, IL-6 and IL-8 concentrations measured normal during the normal range.

Following initiation of amiodarone, she has done well without any recurrence. Her cardiac and inflammatory biomarkers continue to trend downwards (Supplement 1). COVID-19 antibody test (Roche Elecsys Anti-SARS-CoV-2 antibody test, Roche labs, Basel, Switzerland)
was obtained on day 2 of admission and was positive. COVID-19 PCR assay (Cepheid GeneXpert system, Sunnyvale, California, USA) was repeated on post-admission days 8 and 9 and was negative.

**Discussion**

While ventricular dysfunction and the whole gamut of arrhythmias have been reported in adults with acute COVID-19 [1], pediatric patients have either been asymptomatic or have mostly manifested with mild respiratory illness [2]. Rare pediatric patients with COVID-19 have presented with ventricular dysfunction [3]; however, arrhythmias such as A fib, which are exceedingly rare in otherwise healthy children, have not been reported in children with acute COVID-19 [4–9].

A broad range of electrocardiographic abnormalities and arrhythmias such as T wave alterations, ST segment elevation, SI, QIII, TIII pattern, high degree atrioventricular block, atrial tachycardia, atrial flutter, ventricular tachycardia or fibrillation and pulseless electrical activity have been reported in adults with COVID-19 [10]. The pediatric data however remains somewhat limited. In a recently published single center pediatric series (n = 36), nonsustained ventricular tachycardia (n = 5) and sustained atrial tachycardia (n = 1) were noted in approximately 17% of children with acute COVID-19. Of note, all of these arrhythmias self-resolved. However, half of the children in this series were started on an anti-arrhythmic therapy. The electrocardiographic parameters like corrected QT interval were no different between children with and without cardiac arrhythmias [4]. One of these patients was on high dose epinephrine and nor-epinephrine infusions and the other patient had dyselectrolytemia (hypokalemia, hypomagnesemia and hypocalcemia). In addition, abnormal echocardiographic findings such as left ventricular dysfunction, left ventricular dilatation and pericardial effusion were noted in two-thirds of the patients.

A fib in young patients (<18 yrs) is exceedingly rare and is usually associated with alcohol or drug abuse [5], an inherited channelopathy such as Brugada syndrome, long QT syndrome, short QT syndrome or a cardiomyopathy [6,7]. Familial A fib has also been reported in the pediatric population [8]. Children with pre-excitation are also predisposed to A fib which can conduct rapidly to the ventricles [11]. Although children with fulminant myocarditis are predisposed to conduction abnormalities and potentially lethal arrhythmias, A fib has not previously been reported in this population [12,13].

Hypothesized mechanisms of arrhythmias in patients with COVID-19 include downregulation of myocardial and pulmonary ACE2 pathways, leading to myocardial inflammation, lung edema, and acute respiratory failure. Additionally, cytokine storm triggered by an imbalanced response by type 1 and 2 T-helper cells, interferon-mediated immunopathological events, respiratory dysfunction and hypoxemia are also thought to play a role in damaging the myocardium [14]. While elevated plasma soluble IL-2 receptor concentrations which were noted in our patient are known to predispose to atrial fibrillation [15], elevated serum IL-10 concentrations have been shown to be protective in both animal models and humans [16,17]. Additional factors which might have contributed to the genesis of A fib in our patient include severe left ventricular dysfunction induced acute hemodynamic perturbations, leading to an elevation atrial pressure and use of inotropic agents such as milrinone. Short term intravenous infusion (48 h) of milrinone (0.5 μg/kg/min) has been associated with a higher incidence of new onset atrial fibrillation in adults with NYHA class III and IV heart failure (mean left ventricular ejection fraction 23%) [18]. Milrinone use has also been associated with postoperative A fib in both children and adults with heart disease [19,20]. However, except for children with congenital heart disease, the data on association between the use of milrinone and atrial arrhythmias remains limited in the pediatric population.

To the best of our knowledge, this is the first report of A fib in a child with COVID-19 and fulminant myocarditis. These findings are of importance as A fib, especially with rapid ventricular conduction, can lead to acute decompensation in children with marginal ventricular function and can also enhance the risk of thromboembolism to which patients with acute COVID-19 are predisposed. The optimal strategy for anticoagulation in patients with acute COVID-19 and sustained atrial arrhythmias is not known. However, given the heightened risk of thromboembolism with COVID-19, we have maintained our patient on low dose aspirin (81 mg daily) and low molecular weight heparin despite a low CHADS2-Vasc score of 1 (female gender). The optimal duration of anticoagulation for these patients has not been systematically evaluated and therefore remains unknown.

**Funding**

None.
Declarations of Competing Interest

None.

Appendix A. The following are the supplementary data related to this article

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jelectrocard.2020.10.004.

References

[1] Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020;5:831–40. https://doi.org/10.1001/jamacardio.2020.1286.

[2] Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–95. https://doi.org/10.1111/apa.15270.

[3] Oberweis ML, Codreanu A, Boehm W, Olivier D, Pierron C, Tsobo C, et al. Pediatric life-threatening coronavirus disease 2019 with myocarditis. Pediatr Infect Dis J. 2020;39:e147–9. https://doi.org/10.1097/INF.0000000000002744.

[4] Samuel S, Friedman RA, Sharma C, Ganigara M, Mitchell E, Schleien C, et al. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR positive SARS-CoV-2 infection including drug induced changes in the corrected QT interval (QTc). Heart Rhythm. 2020 Jul 1;S1547–959X(20):30632–5. https://doi.org/10.1016/j.hrthm.2020.06.033.

[5] Ramphul K, Joynauth J. Cardiac arrhythmias among teenagers using Cannabis in the United States. Am J Cardiol. 2019;124:1966. https://doi.org/10.1016/j.amjcard.2019.09.002.

[6] Platonov PG, McNitt S, Polonsky S, Rosero SZ, Zareba W. Atrial fibrillation in long QT syndrome by genotype. Circ Arrhythm Electrophysiol. 2019;12:e007213. https://doi.org/10.1161/CIRCEP.119.007213.

[7] Guerard JB, Khairy P, Abadar S, Tadros R, Cadrin-Tourigny J, Macle L, et al. Atrial fibrillation in young patients. Expert Rev Cardiovasc Ther. 2018;16:489–500. https://doi.org/10.1080/14779072.2018.1490644.

[8] Bartos DC, Anderson JR, Bastiaenen R, Johnson JN, Gollob MH, Tester DJ, et al. A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. J Cardiovasc Electrophysiol. 2013;24:562–9. https://doi.org/10.1111/jce.12068.

[9] Kohli U, Lodha R. Cardiac involvement in children with COVID-19. Indian Pediatr. 2020 Aug;7 3007475391600022. Epub ahead of print 32709232.

[10] Haseeb S, Gul EE, Cinier G, Bazoukis G, Alvarez-Garcia J, Garcia-Zamora S, et al. International Society of Electrocardiology Young Community (ISE-YC). Value of electrocardiography in coronavirus disease 2019 (COVID-19). J Electrocardiol. 2020;62:39–45. https://doi.org/10.1016/j.jelectrocard.2020.08.007 Epub ahead of print 32805546. PMC7408671.

[11] Etheridge SP, Escudero CA, Blaufox AD, Law IH, Dechert-Crooks BE, Stephenson EA, et al. Life-threatening event risk in children with Wolff-Parkinson-white syndrome: a multicenter international study. JACC Clin Electrophysiol. 2018;4:433–44. https://doi.org/10.1016/j.jacep.2017.10.009.

[12] Ichikawa R, Suraiitomo N, Kornor A, Abe Y, Nakamura T, Fukuhara J, et al. The follow-up evaluation of electrocardiogram and arrhythmias in children with fulminant myocarditis. Circ J. 2011;75:932–8. https://doi.org/10.1253/circj.10-0918.

[13] Lin KM, Li MH, Hsieh KS, Kuo HC, Cheng MC, Sheu JJ, et al. Impact of extracorporeal membrane oxygenation on acute fulminant myocarditis-related hemodynamic compromise arrhythmia in children. Pediatr Neonatol. 2016;57:480–7. https://doi.org/10.1016/j.pedneo.2016.02.002.

[14] Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31:1003–8. https://doi.org/10.1111/jce.14479.

[15] De Gennaro L, Brunetti ND, Montone D, De Rosa F, Cuculo A, Di Biase M. Inflammatory atrial remodeling and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Investig. 2020;42:371–5. https://doi.org/10.1111/j.1365-2362.2011.05292.x.

[16] Kondo H, Takahashi N, Gotoh K, Fukui A, Saito S, Aoki K, et al. Splenectomy exacerbates atrial inflammatory fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats: possible role of spleen-derived interleukin-10. Heart Rhythm. 2016;13:241–50. https://doi.org/10.1016/j.hrthm.2015.07.001.

[17] Kondo H, Abe I, Gotoh K, Fukui A, Takahari H, Ishii Y, et al. Interleukin 10 treatment ameliorates high-fat diet-induced inflammatory atrial remodeling and fibrillation. Circ Arrhythm Electrophysiol. 2018;11:e006040. https://doi.org/10.1161/CIRCEP.118.006040.

[18] Cuffe MS, Calif RM, Adams Jr RF, Benza R, Bourge R, Colucci WS, et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbations of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7. https://doi.org/10.1001/jama.287.12.15411150176.

[19] Smith AJ, Owen J, Borgman KT, Fish PA, Kannankeril PJ. Relation of milrinone after heart transplantation and inflammatory atrial remodeling. Am J Cardiol. 2011;108:1620–4. https://doi.org/10.1016/j.amjcard.2011.07.023 Epub 2011 Sep 3 321890079. PMC3941037.

[20] Fleming GA, Murray KT, Yu C, Byrne JC, Grealish JP, Petracek MR, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008;118:1619–25. https://doi.org/10.1161/CIRCULATIONAHA.108.790162 Epub 2008 Sep 29. PMID: 18824641; PMCID: PMC2770257.